Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Stem Cells and Development|April 9, 2014
Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cellsRudolf Richter, Andrea Jochheim-Richter, Felicia Ciuculescu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 27, 2019
TLR-Induced IL-12 and CCL2 Production by Myeloid Cells Is Dependent on Adenosine A<sub>3</sub> Receptor-Mediated SignalingCéline van der Putten, Jennifer Veth, Lejla Sukurova, et al.
Current Topics in Medicinal Chemistry|April 8, 2011
Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic spaceEelke van der Horst, Julio E Peironcely, Gerard J P van Westen, et al.
Molecular Pharmacology|April 4, 2020
LUF7244 plus Dofetilide Rescues Aberrant K<sub>v</sub>11.1 Trafficking and Produces Functional I<sub>Kv11.1</sub>Muge Qile, Yuan Ji, Tyona D Golden, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 14, 2008
Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptorsDennis Verzijl, Stefania Storelli, Danny J Scholten, et al.
British Journal of Pharmacology|July 25, 2019
LUF7244, an allosteric modulator/activator of K<sub>v</sub> 11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog modelMuge Qile, Henriette D M Beekman, David J Sprenkeler, et al.
Glia|July 22, 2010
Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesionsRuben Van Doorn, Jack Van Horssen, Dennis Verzijl, et al.
The Journal of Biological Chemistry|January 24, 2004
Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activityPaul J Hensbergen, Dennis Verzijl, Crina I A Balog, et al.
Life Science Alliance|October 22, 2022
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor modelsKristel Kemper, Ellis Gielen, Peter Boross, et al.
Oncoimmunology|February 21, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulationAlexander Muik, Isil Altintas, Friederike Gieseke, et al.
Pageof 8